SHP2-IN-42 

SHP2-IN-42 is a src homology 2 domain-containing phosphatase 2 (SHP2) inhibitor with an IC₅₀ of 15 nM. SHP2-IN-42 inhibits cell proliferation and induces apoptosis and G1 phase cell cycle arrest. SHP2-IN-42 can be used for the research of cancer, such as acute myeloid leukemia (AML)^[1].

SHP2-IN-42 (Compound B8) inhibits cell proliferation with IC₅₀ values of 4.96 μM in MV4-11 cells and 4.25 μM in MOLM-13 cells^[1].
SHP2-IN-42 (2.5-10 μM, 48 h) induces apoptosis in MOLM-13 cells^[1].
SHP2-IN-42 (2.5-10 μM, 24 h) induces G1 phase cell cycle arrest in MOLM-13 cells^[1].
SHP2-IN-42 (2.5-10 μM, 3 h) reduces ERK phosphorylation levels in MOLM-13 cells^[1].
SHP2-IN-42 (3-6 μM, 24 h) induces mitochondrial membrane potential collapse and activation of apoptosis companied with MCL-1 inhibitor VU661013 (HY-112859) in MOLM-13 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

502.56

C₂₇H₃₀N₆O₄

C[C@@H]1OCC2([C@@H]1N)CCN(CC2)C3=NN4C=CC(C5=CC=C(C=C5)N6C=CC=C6C(O)=O)=C4C(N3C)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhang M, et al. Structure-guided expansion strategy unveils potent allosteric SHP2 inhibitors with synergistic efficacy against AML through MCL-1 co-targeting. Eur J Med Chem. 2025 Nov 15;298:117988.  [Content Brief]